Sylvan, S. E., Lundin, J., Ipek, M., Palma, M., Karlsson, C., & Hansson, L. (2014). P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients. BioMed Central.
Citação norma ChicagoSylvan, S Eketorp, J. Lundin, M. Ipek, M. Palma, C. Karlsson, and L. Hansson. P27. Alemtuzumab (anti-CD52 Monoclonal Antibody) As Single-agent Therapy in Patients With Relapsed/refractory Chronic Lymphocytic Leukaemia (CLL) – a Single Region Experience On Consecutive Patients. BioMed Central, 2014.
Citação norma MLASylvan, S Eketorp, et al. P27. Alemtuzumab (anti-CD52 Monoclonal Antibody) As Single-agent Therapy in Patients With Relapsed/refractory Chronic Lymphocytic Leukaemia (CLL) – a Single Region Experience On Consecutive Patients. BioMed Central, 2014.